Anti-Malarial Drugs Market Overview 
Anti-malarial drugs are the medicines used to prevent and treat malaria. They are used for prevention of infection in individuals who travel to malaria-endemic regions. Malaria is the disease caused due to the parasite known as Plasmodium, which belongs to the group of Protozoans. The malaria disease occurs in the tropical, subtropical and temperate regions of the world. Efficient antimalarial therapy not only reduces the illness and mortality of malaria, but also decreases the peril of resistance to antimalarial drugs. The rising prevalence of the malarial disease globally is estimated to enhance the demand of anti-malarial drugs and push the global market.
Market Size & Forecast
The global anti-malarial drugs market is anticipated to record a significant CAGR over a forecast period. The increasing R&D activities for new drugs and new combinations of drugs, due to resistance by the parasites to the currently available drugs, are also expected to drive the global anti-malarial drugs market.
The efficiency of timely diagnosis and effective treatment are the primary technical factors of the global strategy to control malaria are highly dependent on the efficacy, safety, availability, affordability and acceptability of anti-malarial drugs. Efficient antimalarial therapy not only reduces the illness and mortality of malaria, but also decreases the peril of resistance to antimalarial drugs.
On the basis of regional platform, global anti-malarial drugs market and biopharmaceutical oral drug delivery market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region.
Get more information on this report: Download Sample PDF
North America is presently contributing the foremost shares to the global anti-malarial drugs market in terms of revenue and is expected to record a substantial CAGR over the forecast period. Europe is also contributing adequate shares to the market owing to the progressed medical facilities and accessibility of the anti-malarial drugs in the market. Availability of key players, better R&D facilities and better reimbursement policies are the factors driving the growth of this market.
Asia-Pacific is the most profitable market for the anti-malarial drugs due to the elevated incidence of the malarial diseases in the region and is expected to show a robust growth to the global anti-malarial drugs market. Middle East & Africa is at a budding stage of the global anti-malarial drugs market and is projected to register a decent growth of the market over a forecast period.
Market Segmentation
Our-in depth analysis of the global anti-malarial drugs market and biopharmaceutical oral drug delivery market includes the following segments:
By Drug Type
- Quinine
- Chloroquine
- Amodiaquine
- Pyrimethamine
- Proguanil
- Sulfonamide
- Mefloquine
- Atovaquone
- Primaquine
- Artemisinin and derivatives
- Halofantrine
- Doxycycline
- Clindamycin
By Application
- Resistance
- Prevention
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- E- Commerce
The study further incorporates Y-O-Y Growth, demand & supply and forecast future opportunity in North America (United States, Canada), Latin America (Brazil, Mexico, Argentina, Rest of LATAM), Europe (U.K., Germany, France, Italy, Spain, Hungary, BENELUX [Belgium, Netherlands, Luxembourg], NORDIC [Norway, Denmark, Sweden, Finland], Poland, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Indonesia, Taiwan, Hong Kong, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa).
Growth Drivers & Challenges
The rising occurrence of the malarial disease worldwide is anticipated to push the demand of the anti-malarial drugs and drive the global anti-malarial drugs market. Favorable government regulations, development of multi-drug resistance (MDR), and increase in innovation and R&D in terms of anti-malaria therapeutics is estimated to complement market growth.
The strong initiatives taken by the various state governments and regulatory bodies such as U.S. Food and Drug Administration (FDA) to decrease the frequency of malarial disease throughout the world, are also expected to fuel the demand for the anti-malarial drugs and has become one of the element that drives the global anti-malarial drugs market over the forecast period.
However, the probable side effects of the anti-malarial drugs such as vivid dreams, sleeplessness, mental clouding, vertigo and nervousness may impede the demand for the anti-Malarial drug and limit the growth of the global anti-malarial drugs market.
The accessibility of pure quality of drugs in the Southeast Asia and Saharan African countries leads to the inadequate treatment, which may pose a risk to the demand of the anti-malarial drugs and restrict the growth of the global anti-malarial drugs market over the forecast period.
Key Players
- Pfizer
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- GlaxoSmithKline Plc.
- Ranbaxy Laboratories
- Ipca Laboratories Ltd.
- Zydus Cadila
- Merck KGaA
- Novartis AG
- Alvizia Health Care
- Bayer AG
- Roche Inc.
Scope & Context
Overview of the Parent Market
Analyst View
Segmentation
The global anti-malarial drugs market and biopharmaceutical oral drug delivery is segmented as follows:
- By Drug Type Market Size & Y-O-Y Growth Analysis
- By Application Market Size & Y-O-Y Growth Analysis
- By Distribution Channel Type Market Size & Y-O-Y Growth Analysis
- By Region Market Size & Y-O-Y Growth Analysis
Market Dynamics
Supply & Demand Risk
Competitive Landscape
Porter’s Five Force Model
Geographical Economic Activity
Key Players (respective SWOT Analysis) and their Strategies and Product Portfolio
Recent Trends and Developments
Industry Growth Drivers and Challenges
Key Information for Players to establish themselves in current dynamic environment
